Hadassah

Two Hadassah Ophthalmology Articles Are Among Top 100 Most Cited in Four Decades

Thursday, Aug 2 2018

Prof. Jacob Pe'er

Two articles by Hadassah Medical Organization ophthalmologists are among the 100 most cited ophthalmology articles from 1975-2017. One is ranked 11th.

The analysis that revealed this finding was conducted by Singapore researchers and is highlighted in the July 2018 online issue of the British Journal of Ophthalmology. The researchers note that their goal was “to identify and characterize the most influential articles of the past four decades.”

The researchers analyzed both ophthalmology journals and general, non-ophthalmology publications. As Prof. Jaocb Pe’er, Immediate Past Director of Hadassah’s Ophthalmology Department, says, Hadassah’s studies on VEGF (Vascular Endothelial Growth Factor), conducted in collaboration with Prof. Eli Keshet’s laboratory in the Hadassah-Hebrew University Faculty of Medicine, “were a breakthrough in ophthalmology.” Both articles appeared in non-ophthalmology journals. Prof. Pe’er explains that ophthalmologists who perform “serious basic science research always aim to publish in ‘general’ journals, which have a much larger readership.”

First author of one of the articles, which was ranked 11th and cited 1253 times, was Tamar Alon, a PhD student of Prof. Pe’er at the time. It appeared in Nature Medicine in October 1995, entitled “Vascular Endothelial Growth Factor Acts as a Survival Factor for Newly Formed Retinal Vessels and Has Implications for Retinopathy of Prematurity.” The second article, appearing in a 1995 issue of Laboratory Investigation, with Prof. Pe’er as lead author, is entitled “Hypoxia-Induced Expression of Vascular Endothelial Growth Factor by Retinal Cells Is A Common Factor in Neovascularizing Ocular Diseases.” The conclusion highlighted in this article is that “VEGF may be one of the long anticipated factors linking retinal ischemia (oxygen deficiency) and intraocular angiogenesis (formation of new blood vessels). “Irrespective of the cause of retinal ischemia, the article explains, “sustained overproduction of VEGF by ischemic retinal cells may promote retinal and iris neovascularizatiion in a number of neovcascular eye diseases.”

In an editorial in this 1995 issue of Laboratory Investigation entitled “Vascular Endothelial Growth Factor,” the author notes that Prof. Pe’er’s work “provides an elegant anatomic verification of the hypothesis that ischemia, regardless of its etiology, is the major factor responsible for VEGF messengerRNA upregulation in the retina” (an increase in VEGF and thus an overabundance of blood vessels).

It was this discovery, the editorial explains, that offered “fresh hope for a new treatment to preserve vision of patients with diabetic retinopathy and other ophthalmologic blood vessel diseases without risk of serious side effects.” Prof. Pe’er relates that “the author of this editorial was Napoleon Ferrara from Genentech, the company that developed the anti-VEGF drugs, such as Avastin and Lucentis,  which revolutionized the treatment for many ischemic retinal diseases.” Today, he adds, “they are used daily in all eye departments in the world.”

As the Singapore researchers note in the conclusion to their article, their analysis identifies “the landmark articles that have shaped the landscape of ophthalmology and the trends in ophthalmic research over the past four decades.”

Learn more about the Hadassah Medical Organization.

Related Stories

alt_text

Wednesday, Apr 8 2020

Hadassah to Launch Clinical Trials of a Serum to Fight COVID-19

For the first time in Israel, Hadassah Hospital Ein Kerem is collecting plasma from recovered COVID-19 patients...

READ MORE ›
alt_text

Tuesday, Apr 7 2020

Virtual Community Gathering: Israel's Response to the Coronavirus

Israel's experts talk about the Coronavirus, how Israel responded and "best practices" developed via a Zoom panel discussion which included Hadassah Prof. Ran Nir-Paz, Infectious DIsease Physician.

READ MORE ›
alt_text

Tuesday, Apr 7 2020

Hadassah to Initiate Trials of Japanese Drug to Fight COVID-19 READ MORE ›
alt_text

Monday, Apr 6 2020

Hadassah Cardiologist: Don’t Let Fear of COVID-19 Keep You From Urgent Care

The advice to "stay home" should not be heeded if you have chest pains or other signs of a heart attack, warns Hadassah...

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More